These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 15153786

  • 1. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.
    Chao TY, Ho CL, Lee SH, Chen MM, Janckila A, Yam LT.
    J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786
    [Abstract] [Full Text] [Related]

  • 2. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C, Liu Y, Qin H, Li X, Guo W, Li J, Wang W, Qu L, Hu H, Xu C, Zheng L, Huang Y, Liu B, Gao H, Halleen JM, Liu X.
    Clin Chim Acta; 2013 Nov 15; 426():102-7. PubMed ID: 24055775
    [Abstract] [Full Text] [Related]

  • 3. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.
    Halleen JM.
    Anticancer Res; 2003 Nov 15; 23(2A):1027-9. PubMed ID: 12820342
    [Abstract] [Full Text] [Related]

  • 4. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC, Ku CH, Chao TY, Yu JC, Chen MM, Lee SH.
    Cancer Epidemiol Biomarkers Prev; 2006 Mar 15; 15(3):424-8. PubMed ID: 16537696
    [Abstract] [Full Text] [Related]

  • 5. High Uric Acid (UA) Negatively Affects Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) Immunoassay.
    Wu ZQ, Zhang Y, Xie E, Song WJ, Yang RX, Yan CJ, Zhang BF, Xu HG.
    PLoS One; 2016 Mar 15; 11(1):e0147554. PubMed ID: 26800211
    [Abstract] [Full Text] [Related]

  • 6. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis.
    Chao TY, Wu YY, Janckila AJ.
    Clin Chim Acta; 2010 Nov 11; 411(21-22):1553-64. PubMed ID: 20599857
    [Abstract] [Full Text] [Related]

  • 7. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A, Higuchi T, Ozawa H, Yanai A, Miyagawa Y, Murase K, Imamura M, Takatsuka Y, Miyoshi Y.
    Breast Cancer; 2017 Mar 11; 24(2):245-253. PubMed ID: 27040403
    [Abstract] [Full Text] [Related]

  • 8. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
    Wada N, Ishii S, Ikeda T, Enomoto K, Kitajima M.
    Anticancer Res; 1999 Mar 11; 19(5C):4515-21. PubMed ID: 10650803
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the activity of tartrate-resistant acid phosphatase isoform 5b in normal Chinese children--a novel marker for bone growth.
    Chen CJ, Chao TY, Janckila AJ, Cheng SN, Ku CH, Chu DM.
    J Pediatr Endocrinol Metab; 2005 Jan 11; 18(1):55-62. PubMed ID: 15679069
    [Abstract] [Full Text] [Related]

  • 10. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
    Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, Väänänen HK.
    Acta Oncol; 2005 Jan 11; 44(7):742-7. PubMed ID: 16227166
    [Abstract] [Full Text] [Related]

  • 11. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Väänänen HK, Suominen P, Helenius H, Salminen E.
    Anticancer Res; 2006 Jan 11; 26(4B):3127-32. PubMed ID: 16886645
    [Abstract] [Full Text] [Related]

  • 12. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
    Yao NS, Wu YY, Janckila AJ, Ku CH, Hsieh AT, Ho CL, Lee SH, Chao TY.
    Clin Chim Acta; 2011 Jan 14; 412(1-2):181-5. PubMed ID: 20932965
    [Abstract] [Full Text] [Related]

  • 13. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM, Rahemtulla A.
    Int J Cancer; 2003 Sep 01; 106(3):455-7. PubMed ID: 12845688
    [Abstract] [Full Text] [Related]

  • 14. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
    Lyubimova NV, Pashkov MV, Tyulyandin SA, Gol'dberg VE, Kushlinskii NE.
    Bull Exp Biol Med; 2004 Jul 01; 138(1):77-9. PubMed ID: 15514730
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer.
    Capeller B, Caffier H, Sütterlin MW, Dietl J.
    Anticancer Res; 2003 Jul 01; 23(2A):1011-5. PubMed ID: 12820340
    [Abstract] [Full Text] [Related]

  • 16. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
    Mose S, Menzel C, Kurth AA, Obert K, Breidert I, Borowsky K, Böttcher HD.
    Anticancer Res; 2003 Jul 01; 23(3C):2783-8. PubMed ID: 12926113
    [Abstract] [Full Text] [Related]

  • 17. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M.
    Int J Urol; 2008 May 01; 15(5):419-22. PubMed ID: 18452459
    [Abstract] [Full Text] [Related]

  • 18. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis.
    Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT.
    Clin Chim Acta; 2002 Jun 01; 320(1-2):49-58. PubMed ID: 11983200
    [Abstract] [Full Text] [Related]

  • 19. Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis.
    Wu YY, Janckila AJ, Ku CH, Yu CP, Yu JC, Lee SH, Liu HY, Yam LT, Chao TY.
    BMC Cancer; 2010 Apr 23; 10():158. PubMed ID: 20416078
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
    Mose S, Menzel C, Kurth AA, Obert K, Ramm U, Eberlein K, Boettcher HD, Pichlmeier U.
    Anticancer Res; 2005 Apr 23; 25(6C):4639-45. PubMed ID: 16334155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.